Printer Friendly

Arcus Biosciences signs clinical collaboration with Infinity Pharmaceuticals.

M2 PHARMA-June 28, 2018-Arcus Biosciences signs clinical collaboration with Infinity Pharmaceuticals

(C)2018 M2 COMMUNICATIONS

United States-based Arcus Biosciences has signed a clinical collaboration with United States-based Infinity Pharmaceuticals.

It was reported yesterday that the collaboration is aimed at evaluating two triple combination therapies in certain tumour types that typically show minimal response to checkpoint inhibition monotherapy. It will assess IPI-549 in combination with AB928, Arcus's dual adenosine receptor antagonist, and AB122, Arcus's anti-PD-1 antibody, and IPI-549 in combination with AB928 and chemotherapy in patients with triple negative breast cancer (TNBC) or ovarian cancer in four separate cohorts.

These four cohorts will be incorporated into Arcus's recently initiated Phase 1/1b trial to evaluate AB928 combinations in TNBC and ovarian cancer. According to the terms of the contract, both parties will share equally expenses related to the four triple-combination cohorts to assess the safety and activity of IPI-549 + AB928 + AB122 and IPI-549 + AB928 + chemotherapy. Each of the four triple-combination cohorts will enrol around 15 patients. Topline data from these studies are expected in 2019.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 28, 2018
Words:185
Previous Article:Pfizer's Ibrance/fulvestrant combination trial shows no significant extension in overall breast cancer survival.
Next Article:Adicet Bio names new new chief scientific officer.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters